Ebola
Conditions
Interventions
Remdesivir
MBP134
Remdesivir and MBP134
Sponsors
Uganda Ministry of Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) Admitted to a hospital or Ebola Treatment Unit for treatment of Ebola Disease (ii) Positive Ebola RT-PCR (or neonate aged seven days or younger born to a woman with acute laboratory confirmed Ebola Disease) (iii) No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if enrolled in the trial (e.g allergy to a study drug) (iv) Not known to have been enrolled in this protocol previously (v) Not known to have received antiviral (e.g remdesivir or monoclonal antibody) treatment for Ebola Disease during this infection (e.g. through Monitored Emergency Use of Unregistered and Investigational Interventions)
Exclusion criteria
Exclusion criteria: If the attending clinician believes that there is a specific contraindication to one of the active drug treatments and/or that the patient should definitely be receiving one of the active treatments, then they will not be eligible for randomisation in that comparison.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality at 28 days following randomisation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time (days) from randomisation to viral clearance. Viral clearance, using results from routine clinical samples, is defined as the first negative Ebolavirus RT-PCR test without a subsequent positive test result or subsequent death. In the unlikely scenario that a patient is discharged home without two successive negative RT-PCR tests, the date of the first negative test or, if there is no negative test result, the date of medical discharge will be used. | — |
Countries
Uganda
Contacts
Public ContactPauline Byakika Kibwika
Vice Chancellor
Outcome results
None listed